SAN CARLOS, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that preclinical data evaluating recombinant nematode anticoagulant protein c2 (rNAPc2) efficacy in mouse models of primary and metastatic colorectal cancer will be presented in a poster session at the 2006 American Society of Hematology (ASH) Annual Meeting taking place at the Orange County Convention Center in Orlando, FL, December 9-12, 2006.
The presentation details are as follows:
Date/Time: Saturday, December 9, 2006, 5:30-7:30 p.m. EST
Poster Session: Antithrombotic Therapy: Novel Antithrombotics
Abstract # 904: rNAPc2, a Novel Inhibitor of Tissue Factor/Factor VIIa Complex, Suppresses Lung Metastasis and Synergizes with 5-FU or Bevacizumab in Mouse Models of Colorectal Cancer.
All abstracts are currently available online at http://www.abstracts2view.com/hem4806, and appear in the November 16, 2006 issue of Blood, The Journal of The American Society of Hematology.
About rNAPc2
rNAPc2 is a recombinant protein fashioned after one originally isolated from the saliva of the dog hookworm. rNAPc2 blocks the factor VIIa/tissue factor protease complex, which has been shown to play a role in the cellular signaling of both metastasis and angiogenesis in a variety of cancers and is also responsible for the initiation of the process leading to blood clot formation.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, which includes NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
This press release contains "forward-looking statements," which include statements regarding the potential utility of compounds to treat particular indications, the expenses, revenues and the potential for profits from sales of any drug products resulting from such programs, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2006 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
Nuvelo, Inc.CONTACT: Nicole Foderaro, Associate Director of Corporate Communications &IR of Nuvelo, Inc., +1-650-517-8472 or carolyn@weisscommpartners.com; orCarolyn Bumgardner Wang of WeissComm Partners, Inc., +1-415-946-1065 ornfoderaro@nuvelo.com, for Nuvelo, Inc.
Web site: http://www.nuvelo.com/
